Leuthold Group LLC Takes $4.73 Million Position in Gilead Sciences, Inc. $GILD

Leuthold Group LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,636 shares of the biopharmaceutical company’s stock, valued at approximately $4,733,000.

A number of other hedge funds have also bought and sold shares of the company. GoalVest Advisory LLC grew its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences during the 3rd quarter valued at $26,000. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the 2nd quarter valued at $27,000. Putney Financial Group LLC grew its position in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in Gilead Sciences in the second quarter worth $30,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GILD shares. Argus lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. HSBC boosted their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Daiwa Securities Group raised their price objective on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Morgan Stanley boosted their price target on Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday. Twenty-four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $146.44.

Insider Buying and Selling at Gilead Sciences

In other news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 319,391 shares of company stock valued at $44,141,101. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $155.80 on Thursday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a market cap of $193.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36. The company’s 50 day moving average is $129.01 and its 200 day moving average is $121.77.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 51.04%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 beat on top and bottom line: Gilead reported Q4 EPS of $1.86 vs. consensus ~$1.83 and revenue roughly $7.9B, powered by HIV and liver‑disease franchises — the core beat is the primary near‑term driver of the rally. Gilead quarterly results beat Wall Street estimates
• Positive Sentiment: Multiple analyst upgrades/price‑target raises: Banks including Morgan Stanley, JPMorgan, Wells Fargo, Needham and others bumped targets (some to $160–$177+), reinforcing buy/overweight sentiment and supporting the stock pop. Morgan Stanley raises price target
• Positive Sentiment: Yescarta label expansion and pipeline momentum: Positive commentary about CAR‑T (Yescarta) label expansion and new HIV options (Yeztugo) adds optionality to growth expectations. Yescarta label expansion and dividend growth
• Positive Sentiment: Dividend increase: Board raised the quarterly payout to $0.82 (3.8% increase), supporting income investors and reducing equity downside for dividend‑focused holders. Dividend announcement
• Neutral Sentiment: Investor commentary and transcripts: Earnings call and slides are available for detail on unit trends and margin commentary — useful for modeling but not an immediate directional driver. Earnings call transcript
• Neutral Sentiment: Short‑interest items in recent filings show no meaningful or reliable signal (reported zero/odd values), so ignore those as noise.
• Negative Sentiment: FY‑2026 guidance came in slightly light: Gilead set EPS guidance of $8.45–$8.85 and revenue guidance ~$29.6–$30.0B, marginally below consensus (~$30.1B / ~$8.69 EPS), which caused an initial after‑hours pullback and remains the main near‑term risk to sustaining the rally. Guidance story
• Negative Sentiment: Some cautious analyst views remain: A few firms (e.g., RBC with a lower PT) kept conservative ratings/targets, which could cap upside if other brokers re‑rate lower or fundamentals disappoint. Analyst notes (RBC)

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.